Volociximab
Alternative Names: Anti-α5β1 integrin antibody; Eos 200-4; M 200Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator PDL BioPharma
- Developer Abbott Biotherapeutics Corp; Biogen Idec; IVERIC bio; National Cancer Institute (USA); PDL BioPharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Integrin alpha 5 beta 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Intestinal cancer; Non-small cell lung cancer; Peritoneal cancer
- Discontinued Malignant melanoma; Pancreatic cancer; Renal cell carcinoma
Most Recent Events
- 16 Apr 2019 Ophthotech Corporation is now called IVERIC bio
- 04 Nov 2017 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (Intravitreous, Injection)
- 24 Jan 2013 Discontinued - Phase-II for Ovarian cancer (monotherapy, second-line) in USA (IV)